$5.7BTake-privateHealthcare & Life Sciences
KKR's $5.7B Integer buyout clears antitrust review early
Integer Holdings said it received early termination of the Hart-Scott-Rodino waiting period for its pending acquisition by an affiliate of KKR-managed funds. The August 2 merger agreement values the medical device CDMO at $127 per share in cash, or roughly $5.7 billion in enterprise value. Shareholders vote at a special meeting on October 21, and the parties still expect to close by the end of 2026 pending other regulatory approvals.
Why it matters: An early HSR clearance removes the biggest timing risk from one of the year's larger healthcare take-privates.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.